AFP and hepatocellular carcinoma: In the current field of HCC screening, our initial idea on how to integrate the panel with the clinic in the future comes from three sources: (1) the panel can be further used as a complementary testing for patients with AFP-negative or PIVKA-II-negative but with high-risk clinical factors; (2) the panel can be used as a basis for further screening in patients who refuse imaging screening; (3) the panel can improve the detection rate of early HCC and serve as an alternative screening method for people at high risk of HCC.